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Abstract
Purpose: Survivors of breast cancer (BC) on the non-dominant side have more persistent deficits than those with
cancer on the dominant limb. What is not known is whether those with BC use their involved upper limbs more,
less, or at the same level as women without BC. Accelerometer use offers a quantifiable method to measure activity
levels of upper limbs. The purpose of this study was to quantify the activity levels of the non-dominant involved
limb among survivors of BC, and compare these values to their dominant limb, as well as the non-dominant limb of
a control group.
Methods: Participants (n=30) were women with unilateral BC on the non-dominant limb, diagnosed between 6 and
24 months prior to data collection and a matched healthy group of women as controls. Participants completed the
following questionnaires: medical and demographics, Brief Fatigue Inventory, Brief Pain Inventory – Short form,
Disabilities of the Arm, Shoulder and Hand (DASH), and Beck Depression Index. Participants wore an
accelerometer on each wrist during waking hours for seven days. Arm activity was measured using vector
magnitude activity counts extracted from the accelerometers.
Results: There was no significant differences in total vector magnitude activity counts between groups for either
limb. Within group dominant to non-dominant comparison was significantly different (p≤0.001). No significant
difference in pain was present but significant differences for fatigue (p=0.002), depression (p=0.004), and DASH
scores (p=0.035) were present.
Conclusions: Women with non-dominant BC use their involved limb similar to healthy controls but less than their
dominant limb.
Word count for abstract 250 with headings
Key words: Physical function, breast neoplasm, upper extremity, quality of life
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A Quantitative Comparison of Arm Activity between Survivors of Breast Cancer and
Healthy Controls: Use of Accelerometry
Background and Purpose:
Breast cancer (BC), the most commonly diagnosed cancer among women after skin
cancer, was expected to affect more than 268,000 women in 2019 [1]. Over the last 25 years, 5year survival rates have increased to nearly 90% and it is estimated that over three million
women are currently living with BC [1]. Therefore, as women are living beyond diagnosis and
immediate treatment of BC, research is focusing on quality of life (QOL) issues and how long
term deficits which negatively impact QOL can be mitigated.
Survivorship begins at the point of diagnosis and extends throughout life after diagnosis
[2,3]. Understanding how treatment can impact survivorship, both in terms of QOL and overall
function, is important. Lower levels of QOL post-treatment in survivors of BC may be
attributed, in part, to activity limitations and participation restrictions which result from
treatments for BC. Physical function scores on QOL scales decline the greatest immediately
following surgical treatment for BC, but remain below baseline 6-104 weeks after treatment
[4,5]. Treatments for BC including surgical management, chemotherapy, and radiation are
associated with short term upper extremity functional morbidities including loss of motion [6-9],
reduced strength [6,8,10], decline in functional abilities [11], and the development of secondary
lymphedema [12]. These deficits are greater among women who undergo more involved
interventions such as axillary lymph node dissection and mastectomies, and/or axillary radiation,
than the less invasive lumpectomy and/or sentinel lymph node biopsy [13,14]. Furthermore, in a
portion of survivors of BC, those deficits continue longer than the expected healing time after
treatment.
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Research examining the long-term functional status of survivors of BC has shown that
deficits in motion and strength persist beyond the time expected for normal recovery. Range of
motion deficits continued for more than 5 years in 34% of survivors of BC after diagnosis [15],
with two studies reporting the amount of loss exceeding 25° flexion and abduction motion in up
to 38% of survivors of BC 2-4 years after surgery [16,17]. Strength deficits are often selfreported, but in a study of 131 survivors of BC one year following surgery, an 8% loss in
shoulder abduction strength measured by hand-held dynamometry was documented compared to
pre-operative status [18]. In another study of 75 women who underwent both mastectomy and
axillary lymph node dissection with axillary radiation with a mean time since surgery of 15
months, flexion and abduction strength loss was 7 and 18% respectively [19]. Many studies do
not report which limb, the dominant or the non-dominant, is impacted by breast cancer
treatments, despite recording whether the right or the left side is involved. Even in the studies
which do report dominance, no separate analyses were conducted based on the dominance
[19,20,21]. The preponderance of studies that lack detail about which limb is impacted by breast
cancer treatments have the potential to overlook the role of dominance in recovery of upper
extremity function. Yet, some important evidence shows that women who had BC on their nondominant side have more persistent deficits than those who experienced cancer on the dominant
limb. In a study examining 54 women on average four years post diagnosis of unilateral BC,
range of motion, strength and self-reported function were measured and compared to the
respective limb in a group of women without breast cancer. That is to say, the dominant
involved limb of those with breast cancer was compared to the dominant limb of women without
breast cancer, and the non-dominant involved limb of those with breast cancer was compared to
the non-dominant limb of women without breast cancer. The significant findings from this study
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showed differences between those with cancer on their non-dominant side compared to women
with cancer on the dominant side. Importantly, those with cancer on their non-dominant limb
had greater deficits in motion, strength, and self-reported function on the Disabilities of the
Shoulder, Arm and Hand (DASH) than women who did not [22]. It is unclear why the deficits
are greater on the non-dominant involved limb. The greater impairments and disability for those
whose cancer was on the non-dominant side may exist in part because forced usage is expected
on the dominant limb, while the non-dominant limb may not be engaged in the same level of
activity as the dominant side. This premise that women with cancer on their non-dominant limb
use their involved limb less overall needs to be further investigated.
The use of activity trackers or accelerometers is offering objective and quantifiable
methods to measure the amount of activity in which upper limbs are engaged. Acuna and
Karduna [23] established, in a study of 21 workers wearing an accelerometer for a day, that the
amount of activity measured by the device was strongly correlated with the amount of dynamic
activity in which the workers participated (r=0.81-0.97, p<0.01). Other research confirmed the
ability of accelerometers to measure activity at different velocities. In a study examining how
well accelerometers can detect motion, 30 participants wore an accelerometer during
rehabilitation exercises performed at different velocities, while completing tasks mirroring
activities of daily living. The accelerometer was sensitive enough to detect motion at different
velocities (p<0.03), and correlated with visual activity counts for the activities of daily living
(r=.93, p<0.01) [24].
In order to measure the amount of activity between limbs, accelerometers must be
sensitive enough to detect any differences in activity level. In a study comparing the amount of
use on the dominant and non-dominant limbs as well as differences between the involved limb
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and a control group, 15 participants who were to undergo shoulder arthroplasty and 15 matched
controls wore accelerometers for 3 days. Findings from this study revealed both significant
differences between limbs in the experimental group (p<0.001), as well as differences between
the involved limb of the experimental group and the controls (p=0.03) [25]. These results support
similar findings in a study validating the use of accelerometry against a handedness
questionnaire. Forty participants wore accelerometers on both limbs for 24 hours, and a
significant correlation was found between the activity counts of the accelerometers and the
handedness questionnaire [26].
The need to measure limb use among women who experienced BC on their non-dominant
side is important in order to proactively educate women about arm use after BC treatment in
order to mitigate long term deficits. The Prospective Surveillance Model of BC care advocates
for ongoing post-treatment monitoring of functional status in order to prevent morbidities
associated with BC treatments or initiate rehabilitation before impairments impact function in a
more substantial manner [27]. Accelerometry offers a method to objectively quantify upper
extremity activity among survivors of BC. Currently, the authors are unaware of any evidence of
using accelerometers to quantify upper extremity use in survivors of BC, therefore the primary
purpose of this study is to measure bilateral upper extremity activity among women with BC and
a control group. The primary hypothesis of this study is that the non-dominant involved upper
extremity activity of the women treated for BC will be lower than a control group. The
secondary hypothesis is that non-dominant limb activity will be lower than dominant limb
activity in both survivors of BC and a control group.
Methods
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The study recruited thirty women (15 women with unilateral BC on their non-dominant
side and 15 healthy controls) ages 30-69 years between May 2014 - September 2016. Women
with BC were included if they (1) had unilateral cancer stage 0-3, (2) underwent surgical
treatment for breast cancer, (3) had cancer on the non-dominant side, and (4) the cancer
diagnosis was between 6 months and 24 months prior to data collection. The healthy control
group had no history of BC. Exclusion criteria included: (1) any history of shoulder pathology in
the last 6 months other than related to BC; (2) any shoulder, neck, or thoracic surgery; (3)
bilateral cancer, or (5) women with BC who were still currently undergoing BC chemotherapy or
radiation treatment.
Study Design and Procedures
This investigation utilized a matched, case-control study design. This study was a multicentered study with the primary location at the University of Dayton Department of Physical
Therapy, Dayton, Ohio, and the secondary location at Baptist Health Lexington, in Lexington,
Kentucky. Approval was obtained by the Institutional Review Boards at both the University of
Dayton and Baptist Health Lexington prior to initiating the study. After completing informed
consent, participants completed five questionnaires including a medical history with
demographics; fatigue; pain; depression; and arm function.
Medical and Demographics Questionnaire
Participants provided information regarding age, arm dominance, type/stage of cancer,
cancer treatment including type and date of surgery, radiation, and chemotherapy, duration since
diagnosis/treatment initiation, occupational work demand, and shoulder activity level by selfreport. Occupational work demand was rated sedentary, light, medium, heavy, and very heavy,
using the Dictionary of Occupational Titles Physical Demands Checklist [28]. Shoulder activity
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level was measured using ratings of how much lifting, carrying, and overhead manipulation
occurred on a regular basis. These self-reported activity levels were used to determine overall
total self-reported activity. Investigators measured and recorded weight (in kilograms) and height
(in meters) of each participant.
Fatigue: Brief Fatigue Inventory
This 9-item questionnaire is designed to assess the severity and impact of cancer-related
fatigue on daily functional activity in the previous 24 hours. The time required to complete this
scale is approximately 5 minutes. This scale has a reported Cronbach alpha reliability ranging
from 0.82-0.97 [29], and is highly recommended by the Oncology Evidence Database to Guide
Effectiveness (EDGE) Taskforce for use with survivors of BC [30].
Pain: Brief Pain Inventory – Short form
This 11-item questionnaire is designed to assess the severity and interference of pain on
daily functional activity in the previous 24 hours. The time required to complete this scale is
approximately 5 minutes. This scale has a reported Cronbach alpha reliability ranging from 0.770.91 [31], and is highly recommended by the Oncology Evidence Database to Guide
Effectiveness (EDGE) Taskforce for use with survivors of BC [32].
Depression: Beck Depression Index
This 21-item questionnaire measures characteristic attitudes and symptoms of depression
for use in multiple populations. The time required to complete this scale is approximately 10
minutes. This scale has a reported internal consistency (Cronbach alpha) ranging from 0.73-0.92
[33].
Self-reported arm function: Disabilities of the Arm, Shoulder and Hand (DASH)
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This is a reliable and valid 30-item self-report scale scored 0 to 100, with higher scores
indicating greater disability [34]. This scale has been used frequently to assess arm disability and
function among women with breast cancer and is highly recommended by the Oncology
Evidence Database to Guide Effectiveness (EDGE) Taskforce for use with survivors of BC [35].
Quantification of Arm Activity
Participants wore an activity tracker, or accelerometer, on each wrist during waking hours
(6:00 am – 10:30 pm) for seven days. The ActiGraph GT3X+ (Actigraph, Corp., Pensacola, FL)
activity monitor is a tri-axial accelerometer with a mass of 19 grams and physical dimensions of
4.6 cm x 3.3 cm x 1.5 cm. The ActiGraph GT3X+ has the ability to record several measures but
only the vector magnitude physical activity counts (VMPAC) were used in this study. The
ActiGraph GT3X+ was set to record physical activity in the x, y, and z axes every 10 seconds.
This activity tracker was worn during all daily activities but was discouraged during bathing or
activities including water. At the completion of the seven-day period, participants returned to the
lab to turn in the accelerometers. Data from the accelerometers were downloaded to a computer
for further analysis using ActiLife software (Actigraph Corp., Pensacola, FL). The average
hourly VMPAC was calculated by summing the total VMPAC for the waking hours, divided by
the total waking hours. The average hourly VMPAC was used in analysis.
Statistical Analysis
Group demographics were analyzed with descriptive statistics and independent samples ttests for age, body mass, activity level, and self-report questionnaires (Brief Fatigue Inventory,
Brief Pain Inventory, Beck Depression, and DASH). Activity counts were compared between
groups and limbs using independent samples t-tests. To explore the relationship between arm
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activity levels and fatigue, pain, depression, and self-reported function, a correlation analysis
using Pearson r was conducted. The level of significance was set a priori at p <0.05.
Results
Groups were similar across all domains of age, body mass, and total self-reported arm
function (p>0.05). Women with BC were on average 10.5 (1-21) months from surgery. Table 1
details participant demographics.
Independent samples t-test comparisons between groups for the self-report questionnaires
revealed statistically significant differences between survivors of BC and control groups on three
measures. Survivors of BC had higher levels of fatigue (p=0.002), depression (p=0.004) and
scores on the DASH (p=0.035) than women without cancer. No significant differences were
detected in pain levels between groups (p=0.085-0.156). Mean levels of self-reported outcomes
are detailed in Table 2.
Vector magnitude physical activity counts were significantly different between limbs, but
not between groups. Survivors of BC did not use either the involved non-dominant limb or the
non-involved dominant limb any differently than women without BC (p=0.350 and p=0.334,
respectively). Both groups showed significantly less use of the non-dominant limb compared to
the dominate limb (p≤0.001). See Table 3. No relationship between VMPAC and levels of
fatigue, pain, depression or self-reported function (p>0.05) was found.
Discussion
To our knowledge, this was the first study examining quantity of arm motion of women
treated for BC using accelerometry. Results indicate that women with BC appear to use their
limbs at levels comparable to women without BC, in contrast to our hypothesis that this group of
survivors of BC would demonstrated lower arm activity levels than a control group. Our
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hypothesis that the non-dominant limb would demonstrate lower activity levels than the
dominant limb was substantiated. This group of women with cancer on their non-dominant side
used this non-dominant limb less than their dominant limb. This finding is consistent with the
group of women without BC, and with other studies examining the effect of dominance on limb
use [25].
Cancer-related fatigue (CRF) is the most common side effect of cancer treatment, and
prevalence ranges between 58% and 94% for women with breast cancer during treatment, with
overall prevalence reported at 48% throughout the survivorship continuum [36]. The participants
in this study demonstrated greater levels of fatigue and depression than their control
counterparts. Studies investigating CRF also report that depression is associated with CRF, and
together, CRF and depression can result in lower levels of QOL [37,38]. In a secondary analysis
of the women with BC in this study, depression was strongly correlated with fatigue (p<0.001,
r=0.768), consistent with other research findings. In those diagnosed with CRF, lower levels of
physical activity are also reported [39]. Our results do not demonstrate a relationship between
arm activity level and fatigue (p>0.05). It is possible that the results related to arm activity in this
study do not show a difference with a control group because we matched our groups based on
occupational and self-reported arm activity levels.
Women with BC on their non-dominant limb have higher levels of self-reported
disability, and less range of motion and strength than survivors of BC with involvement of their
dominant limbs [22]. In this study, 60% of women had a mastectomy and/or axillary lymph node
dissection, and over half underwent axillary radiation. These treatments typically result in greater
disability than a lumpectomy or sentinel node biopsy. It is possible that the typically occurring
lower levels of activity in the non-dominant involved limb hinder recovery efforts compared to
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women who have BC on the dominant limb. With DASH scores significantly greater among
women with BC compared to the control group in this study, return to full function appears
incomplete. This finding is important to understand within the context of prospective
surveillance education. Rehabilitation specialists should be attentive to encouraging higher levels
of usage of this limb, and should monitor impairment more closely, in order to regain pretreatment levels of functional use of the involved limb.
The DASH questionnaire scores among the survivors of BC group are higher than the
control group, indicating some level of disability. It is important to understand the context of
these findings. The DASH questionnaire is not limb specific. The published directions are to
assess the level of difficulty completing common daily activities [34]. Some questions/activities
are general such as preparing a meal, pushing open a door, carrying items, while other activities
do imply use of dominant limbs. These activities include opening a jar, handling keys, writing
and using a knife, and most of these activities are dominant driven. The groups of women in this
study continue to report deficits despite no involvement of the dominant limb and this suggests
an important role of the non-dominant limb in all activities. It is possible that supportive actions,
such as stabilizing a jar when opening it, or securing food when using a knife, impact overall
upper extremity function. This would need to be more closely examined.
Limitations
This study does present several limitations. This population of survivors of BC focused
only on those with non-dominant involvement and did not include women with cancer on the
dominant side. How the activity levels in this population of women compare to survivors of BC
with cancer on the dominant side is not known. Secondly, accelerometers are limited to
measuring acceleration during motion, but the magnitude of the motion or amount of elevation as
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well as the frequency the arms are lifted overhead cannot be determined. Inertial measurement
units are becoming more available and may allow for more specific motions to be examined in
the future. If the magnitude of motion could be captured, these findings may provide specific
information for recovery of function. Lastly, only one participant had reconstruction. This single
participant’s data did not result in any outliers, and reconstruction was >12 months prior to data
collection. What is not captured in this study is the potential differences in function among
women with reconstruction. This may be especially relevant as the current standard of care has
evolved to reconstruction at the time of mastectomy, before healing of the cancer surgery has
taken place.
Conclusion
This population of breast cancer survivors and controls use the non-dominant involved arm less
than the dominant arm. This could hinder recovery efforts among women with BC on their nondominant limb compared to women who have BC on the dominant limb. In prospective
surveillance education, rehabilitation specialists should be attentive to encouraging higher levels
of usage of this limb, and to monitor impairment more closely to mitigate long-term deficits.
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Table 1. Demographic Characteristics - Mean (SD)

Age (years)
Body Mass Index (kg/m2)
Activity Level
Months from diagnosis
Type of Surgery

Axillary Radiation

Breast Cancer (n = 15)
55 (10)
30.22 (4.41)
13.77 (3.11)

p value
0.763
0.259
0.497

Control (n = 15)
54 (9)
27.89 (6.44)
14.67 (3.70)

10.5 (4.7)
Lumpectomy = 5
Mastectomy = 4
Lumpectomy + ALND = 3
Mastectomy + ALND = 2

-

-

-

-

n=8

-

-

Table 2. Self-Report Measures - Means (SD)
Outcome measure
DASH
Fatigue

Breast cancer ( n=15)
21.57 (24.91)
3.52 (2.17)

Healthy Control (n=15)
4.94 (9.58)
1.24 (1.44)

p value
0.035*
0.002*

Pain Severity
Pain Interference

3.27 (2.11)
2.32 (2.54)

1.73 (1.81)
1.06 (1.52)

0.085
0.156

Beck Depression
11.69 (7.07)
3.27 (2.76)
0.004*
DASH Disability of Arm Shoulder and Hand Questionnaire; BFI Brief Fatigue Inventory; BPI severity Brief
Pain Inventory short form severity; BPI interference Brief Pain Inventory short form interference; Beck
Depression Inventory ; * α significant at the p<0.05 level
Table 3. Arm Activity – Means (SD)
Breast cancer (n=15)

Controls (n=15)

p value

VMPAC Dominant

138,187 (35945)

151,461 (37990)

0.334

VMPAC Non-Dominant

115,123 (31143)

127,214 (38148)

0.350

p value

≤0.001*

≤0.001*

VPMAC = vector magnitude physical activity counts; * α significant at the p<0.05 level
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